Trials / Conditions / Endometrial Adenosquamous Carcinoma

Endometrial Adenosquamous Carcinoma

12 registered clinical trials studyying Endometrial Adenosquamous Carcinoma.

Status	Trial	Sponsor	Phase
Completed	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707	Mayo Clinic	Phase 1
Completed	Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer NCT01935934	National Cancer Institute (NCI)	Phase 2
Completed	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer NCT01210222	Gynecologic Oncology Group	Phase 2
Completed	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer NCT01307631	National Cancer Institute (NCI)	Phase 2
Completed	Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01132820	National Cancer Institute (NCI)	Phase 2
Completed	Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Tr NCT01005329	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carbopla NCT00977574	National Cancer Institute (NCI)	Phase 2
Completed	Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01011933	National Cancer Institute (NCI)	Phase 2
Completed	Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00820898	Gynecologic Oncology Group	Phase 2
Completed	Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV En NCT00575952	Gynecologic Oncology Group	Phase 1
Completed	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus NCT00064025	Gynecologic Oncology Group	Phase 2
Completed	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III NCT00006011	Gynecologic Oncology Group	Phase 3